International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Journal of Clinical Oncology

Volumn 34, Issue 13, 2016, Pages 1544-1557

  Dimopoulos, Meletios A ^a,az   Sonneveld, Pieter ^b   Leung, Nelson ^c   Merlini, Giampaolo ^h   Ludwig, Heinz ^k   Kastritis, Efstathios ^a   Goldschmidt, Hartmut ^l,bm   Joshua, Douglas ⁿ   Orlowski, Robert Z ^d   Powles, Raymond ^o,dl   Vesole, David H ^e   Garderet, Laurent ^p   Einsele, Hermann ^m   Palumbo, Antonio ⁱ   Cavo, Michele ^j,ak   Richardson, Paul G ^f   Moreau, Philippe ^q,de   Miguel, Jesús San ^r   Vincent Rajkumar, S ^c   Durie, Brian G M ^g,bc   Terpos, Evangelos ^a,az   Abildgaard, Niels ^s   Abonour, Rafat ^t   Alsina, Melissa ^u   Anderson, Kenneth C ^f   Attal, Michel ^v   Avet Loiseau, Hervé ^w   Badros, Ashraf ^x   Bahlis, Nizar Jacques ^y   Barlogie, Bart ^z   Bataille, Régis ^aa   Beksaç, Meral ^ab   Belch, Andrew ^ac   Ben Yehuda, Dina ^ad   Bensinger, Bill ^ae   Leif Bergsagel, P ^af   Bhutani, Manisha ^ag   Bird, Jenny ^ah   Bladé, Joan ^ai   Broijl, Annemiek ^b   Boccadoro, Mario ⁱ   Caers, Jo ^aj   Chanan Khan, Asher ^al   Chari, Ajai ^z   Chen, Wen Ming ^am   Chesi, Marta ^af   Anthony Child, J ^an   Chim, Chor Sang ^ao   Chng, Wee Joo ^ap   Comenzo, Ray ^aq   Cook, Gordon ^ar   Crowley, John ^ae   Crusoe, Edvan ^as   Dalton, William ^at   Lee Moffitt, H ^at   Davies, Faith ^au   de la Rubia, Javier ^av   de Souza, Cármino ^aw   Delforge, Michel ^ax   Dhodapkar, Madhav ^ay   Dispenzieri, Angela ^c   Drach, Johannes ^ba   Drake, Matthew ^c   Du, Juan ^bb   Dytfeld, Dominik ^bd   Facon, Theirry ^be   Fantl, Dorotea ^bf   Fermand, Jean Paul ^bg   Fernández de Larrea, Carlos ^ai   Fonseca, Rafael ^af   Gahrton, Gösta ^bh   Garćia Sanz, Ramón ^bi   Gasparetto, Christina ^bj   Gertz, Morie ^c   Ghobrial, Irene ^f   Gibson, John ⁿ   Gimsing, Peter ^bk   Giralt, Sergio ^bl   Gu, Jingli ^bn   Hajek, Roman ^bo   Hardan, Izhar ^bp   Hari, Parameswaran ^bq   Hata, Hiroyuki ^br   Hattori, Yutaka ^bs   Heffner, Tom ^bt   Hillengass, Jens ^bu   Ho, Joy ⁿ   Hoering, Antje ^ae   Hoffman, James Edward ^bv   Hou, Jian ^bb   Huang, Jeffrey ^bw   Hungria, Vania ^bx   Ida, Shinsuke ^by   Jagannath, Sundar ^bz   Jakubowiak, Andrzej J ^ca   Johnsen, Hans Erik ^cb   Jurczyszyn, Artur ^cc   Kaiser, Martin ^cd   Kaufman, Jonathan ^ce   Kawano, Michio ^cf   Korde, Neha ^cg   Kovacs, Eva ^ch   Krishnan, Amrita ^ci   Kristinsson, Sigurdur ^cj   Kröger, Nicolaus ^ck   Kumar, Shaji ^c   Kyle, Robert A ^c   Kyriacou, Chara ^cl   Lacy, Martha ^c   Lahuerta, Juan José ^cm   Landgren, Ola ^bl   Larocca, Alessandra ^cn   Laubach, Jacob ^f   da Costa, Fernando Leal ^co   Lee, Jae Hoon ^cp   Leiba, Merav ^cq   Leleu, Xavier ^cr   Lentzsch, Suzanne ^cs   Lokhorst, Henk ^ct   Lonial, Sagar ^cu   Lu, Jin ^cv   Mahindra, Anuj ^cw   Maiolino, Angelo ^cx   Manasanch, Elisabet E ^cy   Mark, Tomer ^cz   Mateos, María Victoria ^bi   Mazumder, Amitabha ^da   McCarthy, Philip ^db   Mehta, Jayesh ^dc   Mellqvist, Ulf Henrik ^dd   Mikhael, Joseph ^af   Morgan, Gareth ^au   Munshi, Nikhil ^f   Nahi, Hareth ^cj   Nawarawong, Weerasak ^df   Niesvizky, Ruben ^cz   Nouel, Amara ^dg   Novis, Yana ^dh   Ocio, Enrique ^bi   O'Dwyer, Michael ^di   O'Gorman, Peter ^dj   Orfao, Alberto ^bi   Otero, Paula Rodriguez ^r,dt   Paiva, Bruno ^r   Pavlovsky, Santiago ^dk   Pilarski, Linda ^ac   Pratt, Guy ^dm   Qui, Lugui ^dn   Raje, Noopur ^do   Reece, Donna ^dp   Reiman, Anthony ^dq   Remaggi, Guillermina ^dk   Richter, Joshua ^e   Serra, Eloísa Riva ^dr   Morales, Angelina Rodríguez ^ds   Romeril, Kenneth R ^du   Roodman, David ^t   Rosiñol, Laura ^ai   Rossi, Adriana ^cz   Roussel, Murielle ^w   Russell, Stephen ^c   Schjesvold, Fredrik ^dv   Schots, Rik ^dw   Sevcikova, Sabina ^dx   Sezer, Orhan ^dy   Shah, Jatin J ^cy   Shimizu, Kazuyuki ^dz   Shustik, Chaim ^ea   Siegel, David ^e   Singhal, Seema ^dc   Spencer, Andrew ^eb   Stadtmauer, Edward ^ec   Stewart, Keith ^af   Tan, Daryl ^ed   Terragna, Carolina ^ak   Tosi, Patrizia ^ee   Tricot, Guido ^ef   Turesson, Ingemar ^eg   Usmani, Saad ^ag   Van Camp, Ben ^eh   Van de Donk, Niels ^ei   Van Ness, Brian ^ej   Van Riet, Ivan ^eh   Broek, Isabelle Vande ^eh   Vanderkerken, Karin ^eh   Vescio, Robert ^bc   Vij, Ravi ^ek   Voorhees, Peter ^el   Waage, Anders ^em   Wang, Michael ^cy   Weber, Donna ^cy   Weiss, Brendan M ^en   Westin, Jan ^dd   Wheatley, Keith ^eo   Zamagni, Elena ^ak   Zonder, Jeffrey ^ep   Zweegman, Sonja ^ei   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g Samuel Oschin Comprehensive Cancer Institute   (United States)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k WILHELMINEN HOSPITAL   (Austria)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁿ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^o Cancer Centre London   (United Kingdom)

^p HÔPITAL SAINT ANTOINE   (France)

^q HÔTEL DIEU   (France)

^r UNIVERSITY CLINIC OF NAVARRA   (Spain)

^s UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^t INDIANA UNIVERSITY   (United States)

^u H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^v CHU PURPAN   (France)

^w UNIVERSITÉ DE TOULOUSE   (France)

^x UNIVERSITY OF MARYLAND   (United States)

^y UNIVERSITY OF CALGARY   (Canada)

^z MOUNT SINAI MEDICAL CENTER   (United States)

^aa INSTITUT DE BIOLOGIE   (France)

^ab ANKARA UNIVERSITY   (Turkey)

^ac UNIVERSITY OF ALBERTA   (Canada)

^ad HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^ae Fred Hutchinson Cancer Research Center   (United States)

^af MAYO CLINIC   (United States)

^ag LEVINE CANCER INSTITUTE   (United States)

^ah BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^ai HOSPITAL CLÍNIC   (Spain)

^aj UNIVERSITY OF LIÈGE   (Belgium)

^ak UNIVERSITY OF BOLOGNA   (Italy)

^al MAYO CLINIC   (United States)

^am CAPITAL MEDICAL UNIVERSITY   (China)

^an United Leeds Teaching Hospitals   (United Kingdom)

^ao QUEEN MARY HOSPITAL   (Hong Kong)

^ap NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^aq TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ar UNIVERSITY OF LEEDS   (United Kingdom)

^as FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^at University of Arkansas for Medical Sciences ^*  (United States)

^au UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^av HOSPITAL UNIVERSITARIO LA FE   (Spain)

^aw Univeridade de Campinas   (Brazil)

^ax UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ay YALE CANCER CENTER   (United States)

^az UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ba UNIVERSITY OF VIENNA   (Austria)

^bb SECOND MILITARY MEDICAL UNIVERSITY   (China)

^bc CEDARS SINAI MEDICAL CENTER   (United States)

^bd POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^be UNIV LILLE   (France)

^bf Socieded Argentinade Hematolgia   (Argentina)

^bg SAINT LOUIS HOSPITAL   (France)

^bh KAROLINSKA INSTITUTE   (Sweden)

^bi HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^bj DUKE UNIVERSITY MEDICAL CENTER   (United States)

^bk UNIVERSITY OF COPENHAGEN   (Denmark)

^bl MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bm UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^bn SUN YAT SEN UNIVERSITY   (China)

^bo UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^bp TEL AVIV UNIVERSITY   (Israel)

^bq MEDICAL COLLEGE OF WISCONSIN   (United States)

^br KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^bs KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^bt EMORY UNIVERSITY   (United States)

^bu UNIVERSITY OF HEIDELBERG   (Germany)

^bv UNIVERSITY OF MIAMI   (United States)

^bw NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^bx São Germano Clinic   (Brazil)

^by NAGOYA CITY UNIVERSITY   (Japan)

^bz Mt Sinai Tisch Cancer Institute   (United States)

^ca UNIVERSITY OF CHICAGO   (United States)

^cb AALBORG UNIVERSITY HOSPITAL   (Denmark)

^cc UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^cd ROYAL MARSDEN HOSPITAL   (United Kingdom)

^ce EMORY CLINIC   (United States)

^cf YAMAGUCHI UNIVERSITY   (Japan)

^cg NATIONAL INSTITUTES OF HEALTH   (United States)

^ch Cancer Immunology Research   (Switzerland)

^ci CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^cj KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ck UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^cl NORTHWICK PARK HOSPITAL   (United Kingdom)

^cm HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^cn Dipto di Med e Oncol Sperimentale Div Universitaria di Ematologia   (Italy)

^co INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^cp Gachon University   (South Korea)

^cq SHEBA MEDICAL CENTER   (Israel)

^cr LILLE UNIVERSITY HOSPITAL   (France)

^cs Instituto Portugues De Oncologia ^*  (United States)

^ct UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^cu EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^cv PEKING UNIVERSITY   (China)

^cw UNIVERSITY OF CALIFORNIA   (United States)

^cx University Medical Center Utrecht ^*  (Brazil)

^cy UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^cz WEILL CORNELL MEDICAL COLLEGE   (United States)

^da NEW YORK UNIVERSITY   (United States)

^db ROSWELL PARK CANCER INSTITUTE   (United States)

^dc NORTHWESTERN UNIVERSITY   (United States)

^dd SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^de NANTES UNIVERSITY HOSPITAL   (France)

^df CHIANG MAI UNIVERSITY   (Thailand)

^dg Hospital Rutz y Paez   (Venezuela)

^dh HOSPITAL SÍRIO LIBANÊS   (Brazil)

^di NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^dj MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^dk Fundacion para Combatir La Leucemia   (Argentina)

^dl Parkside Cancer Centre   (United Kingdom)

^dm UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^dn INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^do MASSACHUSETTS GENERAL HOSPITAL   (United States)

^dp PRINCESS MARGARET HOSPITAL   (Canada)

^dq SAINT JOHN REGIONAL HOSPITAL   (Canada)

^dr HOSPITAL DE CLÍNICAS   (Uruguay)

^ds Bonco Metro Politano de Sangre   (Venezuela)

^dt UNIVERSITY OF NAVARRA   (Spain)

^du WELLINGTON HOSPITAL   (New Zealand)

^dv OSLO UNIVERSITY HOSPITAL   (Norway)

^dw UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^dx MASARYK UNIVERSITY   (Czech Republic)

^dy Memorial Sisli Hastanesi   (Turkey)

^dz Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^ea MCGILL UNIVERSITY   (Canada)

^eb ALFRED HOSPITAL   (Australia)

^ec UNIVERSITY OF PENNSYLVANIA   (United States)

^ed SINGAPORE GENERAL HOSPITAL   (Singapore)

^ee Istituto di Ematologia Seragnoli   (Italy)

^ef UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^eg LUND UNIVERSITY HOSPITAL   (Sweden)

^eh VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^ei VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ej UNIVERSITY OF MINNESOTA   (United States)

^ek WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^el UNIVERSITY OF NORTH CAROLINA   (United States)

^em TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^en UNIVERSITY OF PENNSYLVANIA   (United States)

^eo UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^ep KARMANOS CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELECTROLYTE; IXAZOMIB; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS MEMBRANE; DISEASE ASSESSMENT; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEASIBILITY STUDY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; LIGHT CHAIN; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIAGNOSIS; RENAL INSUFFICIENCY;

HUMANS; MULTIPLE MYELOMA; RENAL INSUFFICIENCY;

EID: 84965050407     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.0044     Document Type: Article

References (101)

1. Riccardi A, Gobbi PG, Ucci G, et al: Changing clinical presentation of multiple myeloma. Eur J Cancer 27:1401-1405, 1991.
2. Abbott KC, Agodoa LY: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival. Clin Nephrol 56:207-210, 2001.
3. Tsakiris DJ, Stel VS, Finne P, et al: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERAEDTA Registry study. Nephrol Dial Transplant 25: 1200-1206, 2010.
4. Augustson BM, Begum G, Dunn JA, et al: Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23:9219-9226, 2005.
5. Dimopoulos MA, Delimpasi S, Katodritou E, et al: Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25:195-200, 2014.
6. Uttervall K, Duru AD, Lund J, et al: The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One 9:e101819, 2014.
7. Khan R, Apewokin S, Grazziutti M, et al: Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia 29:1195-1201, 2015.
8. Atkins D, Best D, Briss PA, et al: Grading quality of evidence and strength of recommendations. BMJ 328:1490, 2004.
9. Dimopoulos MA, Kastritis E, Rosinol L, et al: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493, 2008.
10. Hutchison CA, Batuman V, Behrens J, et al: The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8:43-51, 2012.
11. Kastritis E, Terpos E, Dimopoulos MA: Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother 14:1477-1495, 2013.
12. Huang ZQ, Sanders PW: Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 73:810-817, 1995.
13. Sengul S, Zwizinski C, Simon EE, et al: Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 62:1977-1988, 2002.
14. From AM, Bartholmai BJ, Williams AW, et al: Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: A retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol 3:10-18, 2008.
15. Nasr SH, Valeri AM, Sethi S, et al: Clinicopathologic correlations in multiple myeloma: A case series of 190 patients with kidney biopsies. Am J Kidney Dis 59:786-794, 2012.
16. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596, 2003.
17. Buxbaum J, Gallo G: Nonamyloidotic monoclonal immunoglobulin deposition disease. Lightchain, heavy-chain, and light- And heavy-chain deposition diseases. Hematol Oncol Clin North Am 13: 1235-1248, 1999.
18. Bridoux F, Leung N, Hutchison CA, et al: Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87:698-711, 2015.
19. Fermand JP, Bridoux F, Kyle RA, et al: How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122:3583-3590, 2013.
20. Rajkumar SV, Dimopoulos MA, Palumbo A, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-e548, 2014.
21. Masson I, Flamant M, Maillard N, et al: MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients. Transplantation 95:1211-1217, 2013.
22. Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20-29, 2012.
23. Levey AS, Eckardt KU, Tsukamoto Y, et al: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
24. Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612, 2009.
25. Michels WM, Grootendorst DC, Verduijn M, et al: Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5:1003-1009, 2010.
26. Dimopoulos MA, Terpos E, Symeonidis AS, et al: Estimated glomerular filtration rate calculated by the CKD-EPI formula has improved prognostic ability over MDRD formula in patients with newly diagnosed, symptomatic, multiple myeloma: Analysis in 1937 patients. Blood 122:1867, 2013 (abstr).
27. Terpos E, Christoulas D, Kastritis E, et al: The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPICysC equations? Eur J Haematol 91:347-355, 2013.
28. Terpos E, Katodritou E, Tsiftsakis E, et al: Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 94: 372-379, 2009.
29. Palumbo A, Avet-Loiseau H, Oliva S, et al: Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 33:2863-2869, 2015.
30. Srisawat N, Hoste EE, Kellum JA: Modern classification of acute kidney injury. Blood Purif 29: 300-307, 2010.
31. Ando M, Mori J, Ohashi K, et al: A comparative assessment of the RIFLE, AKIN and conventionalcriteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplant 45:1427-1434, 2010.
32. Shi H, Zhang W, Li X, et al: Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: S 15-year retrospective, single center, cohort study. Leuk Lymphoma 55:1076-1082, 2014.
33. Leung N, Gertz M, Kyle RA, et al: Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathyrelated kidney diseases. Clin J Am Soc Nephrol 7: 1964-1968, 2012.
34. Dimopoulos MA, Terpos E: Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program 2010:431-436, 2010.
35. Merlini G, Palladini G: Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012:595-603, 2012.
36. Dimopoulos MA, Terpos E, Chanan-Khan A, et al: Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976-4984, 2010.
37. Morabito F, GentileM, Mazzone C, et al: Safety and efficacy of bortezomib-melphalan-prednisonethalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 118:5759-5766, 2011.
38. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al: The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27: 423-429, 2013.
39. Pö nisch W, Moll B, Bourgeois M, et al: Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 139:1937-1946, 2013.
40. Park S, Han B, Kim K, et al: Renal Insufficiency in newly-diagnosed multiple myeloma: Analysis according to International Myeloma Working Group consensus statement. Anticancer Res 34: 4299-4306, 2014.
41. Ludwig H, Rauch E, Kuehr T, et al: Lenalidomide and dexamethasone for acute light chaininduced renal failure: A phase II study. Haematologica 100:385-391, 2015.
42. Dimopoulos MA, Terpos E, Roussou M, et al: Validation of criteria for renal response in patients with multiple myeloma (MM) who present with severe renal dysfunction. Blood 122:3176, 2013 (abstr).
43. Palumbo A, Rajkumar SV, San Miguel JF, et al: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32:587-600, 2014.
44. MRC Working Party on Leukaemia in Adults: Analysis and management of renal failure in fourth MRC myelomatosis trial. Br Med J (Clin Res Ed) 288: 1411-1416, 1984.
45. Terpos E, Morgan G, Dimopoulos MA, et al: International Myeloma Working Group recommendations for the treatment of multiple myelomarelated bone disease. J Clin Oncol 31:2347-2357, 2013.
46. Watkins KR, Rogers JE, Atkinson B: Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer 23:1657-1662, 2015.
47. Sanders PW, Booker BB: Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 89:630-639, 1992.
48. Pozzi C, Pasquali S, Donini U, et al: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol 28:1-9, 1987.
49. Zucchelli P, Pasquali S, Cagnoli L, et al: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33: 1175-1180, 1988.
50. Johnson WJ, Kyle RA, Pineda AA, et al: Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150:863-869, 1990.
51. Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 143:777-784, 2005.
52. Burnette BL, Leung N, Rajkumar SV: Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 364:2365-2366, 2011.
53. Yu X, Gan L, Wang Z, et al: Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: A meta-analysis. Int J Clin Pharmacol Ther 53:391-397, 2015.
54. Hutchison CA, Heyne N, Airia P, et al: Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 27:3823-3828, 2012.
55. Heyne N, Denecke B, Guthoff M, et al: Extracorporeal light chain elimination: High cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 91:729-735, 2012.
56. Zannetti BA, Zamagni E, Santostefano M, et al: Bortezomib-based therapy combined with high cutoff hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol 90:647-652, 2015.
57. Torra R, Bladé J, Cases A, et al: Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91:854-859, 1995.
58. Irish AB, Winearls CG, Littlewood T: Presentation and survival of patients with severe renal failure and myeloma. QJM 90:773-780, 1997.
59. Gonsalves WI, Leung N, Rajkumar SV, et al: Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296, 2015.
60. Cooper EH, Forbes MA, Crockson RA, et al: Proximal renal tubular function in myelomatosis: Observations in the fourth Medical Research Council trial. J Clin Pathol 37:852-858, 1984.
61. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol 65:175-181, 2000.
62. Dimopoulos MA, Richardson PG, Schlag R, et al: VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 27: 6086-6093, 2009.
63. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990.
64. Bladé J, Fernández-Llama P, Bosch F, et al: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889-1893, 1998.
65. Bayraktar UD, Warsch S, Pereira D: High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. Am J Hematol 86:224-227, 2011.
66. Kastritis E, Anagnostopoulos A, Roussou M, et al: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546-549, 2007.
67. Fakhouri F, Guerraoui H, Presne C, et al: Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 125:96-97, 2004.
68. Tosi P, Zamagni E, Cellini C, et al: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73: 98-103, 2004.
69. Tosi P, Zamagni E, Tacchetti P, et al: Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosedmultiplemyeloma and renal insufficiency. Biol Blood Marrow Transplant 16: 1115-1121, 2010.
70. Niesvizky R, Naib T, Christos PJ, et al: Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-näive patients undergoing frontline lenalidomide and dexamethasone therapy. Br J Haematol 138:640-643, 2007.
71. Dimopoulos M, Alegre A, Stadtmauer EA, et al: The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116:3807-3814, 2010.
72. De la Rubia J, Roig M, Ibañez A, et al: Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study. Eur J Haematol 85:363-365, 2010.
73. Dimopoulos MA, Christoulas D, Roussou M, et al: Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 85: 1-5, 2010.
74. Klein U, Neben K, Hielscher T, et al: Lenalidomide in combination with dexamethasone: Effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 90:429-439, 2011.
75. Zhou DB, Yu L, Du X, et al: Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hematol 101:569-577, 2015.
76. Dimopoulos MA, Cheung MC, Roussel M, et al: Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica pii: haematol.2015.133629, 2015 (in press).
77. Weisel KC, Dimopoulos MA, Cavo M, et al: Pomalidomide plus low-dose dexamethasone in patients with relapsed or relapsed and refractorymultiple myeloma and renal impairment: Analysis of patients from the phase 3b STRATUS trial (MM-010). Blood 124:4755, 2014 (abstr).
78. Roussou M, Kastritis E, Christoulas D, et al: Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34:1395-1397, 2010.
79. Harris E, Behrens J, Samson D, et al: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 122:160-161, 2003.
80. Dimopoulos MA, Palumbo A, Attal M, et al: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement. Leukemia 25:749-760, 2011.
81. Dimopoulos MA, Leleu X, Palumbo A, et al: Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28:1573-1585, 2014.
82. Jagannath S, Barlogie B, Berenson JR, et al: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 103:1195-1200, 2005.
83. San-Miguel JF, Richardson PG, Sonneveld P, et al: Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia 22:842-849, 2008.
84. Bladé J, Sonneveld P, San Miguel JF, et al: Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patientswith renal function impairment. Clin Lymphoma Myeloma 8:352-355, 2008.
85. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al: Reversibility of renal impairment in patients with multiple myeloma treated with bortezomibbased regimens: Identification of predictive factors. Clin Lymphoma Myeloma 9:302-306, 2009.
86. Ludwig H, Adam Z, Hajek R, et al: Light chaininduced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 28: 4635-4641, 2010.
87. Morabito F, Gentile M, Ciolli S, et al: Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 84:223-228, 2010.
88. Scheid C, Sonneveld P, Schmidt-Wolf IG, et al: Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 99: 148-154, 2014.
89. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al: Bortezomib-based triplets are associatedwith a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol doi:10.1002/ajh.24335, 2016 (in press).
90. Sonneveld P, Salwender H, van der Holt B, et al: Long term follow up of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib vs standard treatment in patients with multiple myeloma. Blood 126:27, 2015 (abstr).
91. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica 100: E207-e210, 2015.
92. Merz M, Salwender H, Haenel M, et al: Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: An interim analysis from the prospective GMMG-MM5 trial. Haematologica 100: 964-969, 2015.
93. Badros AZ, Vij R, Martin T, et al: Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. Leukemia 27:1707-1714, 2013.
94. Dimopoulos MA, Moreau P, Palumbo A, et al: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomized, phase 3, open-label, multicenter study. Lancet Oncol 17:27-38, 2016.
95. Moreau P, Masszi T, Grzasko N, et al: Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progressionfree survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The phase 3 Tourmaline-MM1 study. Blood 126:727, 2015 (abstr).
96. San Miguel JF, Lahuerta JJ, Garćia-Sanz R, et al: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 1:28-36, 2000.
97. Badros A, Barlogie B, Siegel E, et al: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114: 822-829, 2001.
98. Lee CK, Zangari M, Barlogie B, et al: Dialysisdependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 33:823-828, 2004.
99. Parikh GC, Amjad AI, Saliba RM, et al: Autologous hematopoietic stem cell transplantation may reverse renal failure in patientswithmultiplemyeloma. Biol Blood Marrow Transplant 15:812-816, 2009.
100. Breitkreutz I, Heiss C, Perne A, et al: Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant 49:1371-1375, 2014.
101. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al: Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 91: 672-676, 2011.